This continuing education activity is derived from content presented at the 2019 ASHP Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada. The program will highlight recent advances in antiplatelet therapeutics for acute coronary syndrome. The expert faculty will analyze current guidelines and provide insight into best approaches for developing effective patient-specific treatment plans that include the clinical pharmacy team. Navigating combination therapies while optimizing duration of antiplatelet therapies in the ACS patient will be reviewed in an interactive panel format. The faculty will also discuss the role of the pharmacist in the cardiac catheterization laboratory, covering procedural best practices, medication reconciliation, and patient education. This activity will provide learners with a better understanding of acute coronary syndrome and the central role of platelet inhibition during early management, particularly in the catherization lab, to improve treatment and management in their pharmacy practice.
Pharmacists, cardiologists, primary care physicians, PAs, NPs, nurses, and other healthcare professionals involved in the management of patients with ACS
- Review current guidelines for antiplatelet therapies for ACS to develop the most effective patient-specific treatment plans
- Analyze the latest clinical trial data of antiplatelet agents for the treatment of patients with ACS
- Identify an optimal pharmacist role in the cardiac catheterization laboratory
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Snehal H. Bhatt, PharmD||Consultant/Advisor: Janssen Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.
Speaker’s Bureau: Janssen Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.
|John Fanikos, RPh, MBA||Nothing to disclose.|
|Charles V. Pollack Jr., MD, MA||Consultant/Advisor: AstraZeneca Pharmaceuticals
Research/Grant Support: AstraZeneca Pharmaceuticals
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this live material for a maximum of 1.50 CNE Contact Hours, including 1.50 pharmacotherapeutic contact hours (Provider number P0491).
AcademicCME designates this continuing education activity for 1.50 CPE Contact Hours (0.15 CEUs) of continuing pharmacy education credit (JA4008190-0000-19-008-H01-P).
This activity has been supported by an independent educational grant from Chiesi USA, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Chiesi USA, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1.Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
6. Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].